Health News
Stay informed with the latest health industry news from around the globe. Read about advancements in health technology, updates in health insurance, innovations in medical devices, and more. Keep up with important health trends and industry developments.
Jun 5, 2026 at 5:38 PM
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It
GENEVA--(BUSINESS WIRE)--Today P&G Oral Care announces the release of a new, first-of-its kind LCA study published in the Journal of Dentistry finds managing advanced periodontal disease can be associated with up to ~10× higher environmental impact compared with maintaining periodontal health through at-home prevention. The peer-reviewed paper, titled “Quantifying the Environmental Impact Potential from Periodontal Health to Disease: Findings from a Life Cycle Assessment Study,” for the fir...
Jun 5, 2026 at 4:35 PM
AM Best Affirms Credit Ratings of CVS Health Corporation’s Aetna Inc. Subsidiaries
OLDWICK, N.J.--(BUSINESS WIRE)--AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a” (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE: CVS). (Please see below for a detailed listing of the compani...
Jun 5, 2026 at 4:01 PM
SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F
BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 (the “Annual Report”) with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed at the Company's website at www.sinovac.com.cn or www.sinovac.com and at the SEC’s website www.sec.gov. The Company also...
Jun 5, 2026 at 4:01 PM
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder and CEO Eric Lefkofsky will participate in a fireside chat at 2:00 p.m. ET on Monday, June 8. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision medicine through the practi...
Jun 5, 2026 at 4:00 PM
CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026
SHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at the American Diabetes Association (ADA) Scientific Sessions 2026. The data demonstrated robust weight reduction, preservation of lean mass, reduced weight regain following treatment discontinuation and the potential for extended dosing intervals. CC-18 is designed to address a growing challenge in...
Jun 5, 2026 at 2:40 PM
Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity
BOULDER, Colo.--(BUSINESS WIRE)--At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories has been studying skin cells to better understand what supports the visible qualities associated with healthier-looking, more resilient skin over time. While much of the longevity conversation has centered on high-profile molecules associated with NAD+ and “breakthrough” molecules, AV Laboratories’ recent research points back to something more fundamental: amino acids. Wi...
Jun 5, 2026 at 1:59 PM
Brighton Marine Names Brian J. Ewart General Counsel
BOSTON--(BUSINESS WIRE)--Brighton Marine today announced the appointment of Brian J. Ewart as General Counsel. Ewart will provide strategic legal counsel and oversight across Brighton Marine and its affiliated enterprises, supporting the organization’s healthcare, housing, and wraparound service initiatives for veterans and military-connected families. Ewart joined Brighton Marine as Deputy General Counsel and has played a key role guiding and supporting the organization’s legal, compliance, go...
Jun 5, 2026 at 12:00 PM
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, pres...
Jun 5, 2026 at 12:00 PM
Feinstein Institutes’ John M. Kane honored with 2026 Schizophrenia International Research Society Lifetime Achievement Award
MANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded the 2026 Lifetime Achievement Award from the Schizophrenia International Research Society (SIRS). This recognition celebrates his decades-long contributions that have transformed the understanding, treatment and outcomes for individuals living with schizophrenia worldwide. The SIRS Lifetime Achievement Award is one of...
Jun 5, 2026 at 11:09 AM
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
AUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand the approved Marketing Authorization Application (MAA) for AQNEURSA® (levacetylleucine) to include the treatment of Ataxia-Telangiectasia (A-T). This submission represents the first regulatory application submitted to the EMA seeking approval of a therapy for the treatment of A-T, a rare, progressive, inherited neurodegenerative disorder. The v...
Media & Journalist Tools
From headlines to storylines—Business Wire delivers the news you need, when you need it.